Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Retained Earnings (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Retained Earnings for 6 consecutive years, with $733000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 173.97% to $733000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $733000.0 through Dec 2025, up 173.97% year-over-year, with the annual reading at $733000.0 for FY2025, 173.97% up from the prior year.
  • Retained Earnings for Q4 2025 was $733000.0 at Relay Therapeutics, up from -$2.0 billion in the prior quarter.
  • The five-year high for Retained Earnings was $733000.0 in Q4 2025, with the low at -$2.0 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$848.8 million, with a median of -$868.5 million recorded in 2022.
  • The sharpest move saw Retained Earnings crashed 1200256.25% in 2021, then skyrocketed 173.97% in 2025.
  • Over 5 years, Retained Earnings stood at -$768.1 million in 2021, then crashed by 37.82% to -$1.1 billion in 2022, then crashed by 32.3% to -$1.4 billion in 2023, then soared by 99.93% to -$991000.0 in 2024, then surged by 173.97% to $733000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $733000.0, -$2.0 billion, and -$163000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.